Sisomicin

	WikiDoc Resources for Sisomicin
Articles
Most recent articles on Sisomicin Most cited articles on Sisomicin Review articles on Sisomicin Articles on Sisomicin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Sisomicin Images of Sisomicin Photos of Sisomicin Podcasts & MP3s on Sisomicin Videos on Sisomicin
Evidence Based Medicine
Cochrane Collaboration on Sisomicin Bandolier on Sisomicin TRIP on Sisomicin
Clinical Trials
Ongoing Trials on Sisomicin at Clinical Trials.gov Trial results on Sisomicin Clinical Trials on Sisomicin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Sisomicin NICE Guidance on Sisomicin NHS PRODIGY Guidance FDA on Sisomicin CDC on Sisomicin
Books
Books on Sisomicin
News
Sisomicin in the news Be alerted to news on Sisomicin News trends on Sisomicin
Commentary
Blogs on Sisomicin
Definitions
Definitions of Sisomicin
Patient Resources / Community
Patient resources on Sisomicin Discussion groups on Sisomicin Patient Handouts on Sisomicin Directions to Hospitals Treating Sisomicin Risk calculators and risk factors for Sisomicin
Healthcare Provider Resources
Symptoms of Sisomicin Causes & Risk Factors for Sisomicin Diagnostic studies for Sisomicin Treatment of Sisomicin
Continuing Medical Education (CME)
CME Programs on Sisomicin
International
Sisomicin en Espanol Sisomicin en Francais
Business
Sisomicin in the Marketplace Patents on Sisomicin
Experimental / Informatics
List of terms related to Sisomicin

Sisomicin
Clinical data
Trade names	bactoCeaze
AHFS/Drugs.com	International Drug Names
Routes of; administration	topical
ATC code	J01GB08 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name (2R,3R,4R,5R)-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol;
PubChem CID	36119;
UNII	X55XSL74YQ;
KEGG	D02544 ;
ChEMBL	ChEMBL606051 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C19H37N5O7
Molar mass	447.53 g/mol
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Sisomicin (bactoCeaze or Ensamycin) is an aminoglycoside antibiotic, isolated from the fermentation broth of a new species of the genus Micromonospora.^[1] It is a newer broad-spectrum aminoglycoside most structurally related to gentamicin.

Sisomicin is the most predictably active aminoglycoside against gram-positive bacteria.^[2] Like most other aminoglycosides, Sisomicin is bactericidal for sensitive clinical isolates. The minimum bactericidal concentrations (MBC) have been found to be equivalent or very close to the minimum inhibitory concentrations (MIC).^[2] Like other aminoglycosides, most clinical isolates of Pseudomonas aeruginosa remain susceptible to sisomicin. Resistance to sisomicin may enzymatically or non-enzymatically be mediated. Sisomicin is inactivated by the same enzymes as gentamicin but it is active against many, not all, organisms that resist gentamicin by non-enzymatic mechanisms.^[3]

Some studies show that sisomicin has been effective in the treatment of infections that either had failed to respond to other drugs or were due to microorganisms resistant in vitro to other aminoglycosides.^[4]^[5]

References

↑ M. J. Weinstein, J. A. Marquez, R. T. Testa, G. H. Wagman, E. M. Oden, J. A. Waitz (Nov 1970). "Antibiotic 6640, a new Micromonospora-produced aminoglycoside antibiotic". J. Antibiot. 23 (11): 551–554. doi:10.7164/antibiotics.23.551. PMID 5487129.
↑ ^2.0 ^2.1 WE Sanders Jr, CC Sanders. (Mar–Apr 1980). "Sisomicin: a review of eight years' experience". Rev Infect Dis. 2 (2): 182–195. doi:10.1093/clinids/2.2.182. PMID 6994206.
↑ I Phillips, BA King, KP Shannon. (Mar 1978). "The mechanisms of resistance to aminoglycosides in the genus Pseudomonas". J Antimicrob Chemother. 4 (2): 121–129. doi:10.1093/jac/4.2.121. PMID 649532.
↑ ME Levison, D Kaye. (Mar 1979). "A randomized comparative trial of three aminoglycosides--comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies". Medicine (Baltimore). 58 (2): 159–170. doi:10.1097/00005792-197903000-00004. PMID 431401.
↑ DG Maki, WA Craig, WA Agger. (Jun 1979). "A comparative clinical trial of sisomicin and gentamicin in major gram-negative infections". Infection 7(Suppl. 3). 5 (6): 298–300. doi:10.1007/bf01646260.

Template:AminoglycosideAntiBiotics

[pmid5487129-1] M. J. Weinstein, J. A. Marquez, R. T. Testa, G. H. Wagman, E. M. Oden, J. A. Waitz (Nov 1970). "Antibiotic 6640, a new Micromonospora-produced aminoglycoside antibiotic". J. Antibiot. 23 (11): 551–554. doi:10.7164/antibiotics.23.551. PMID 5487129.

[pmid6994206-2] 2.0 ^2.1 WE Sanders Jr, CC Sanders. (Mar–Apr 1980). "Sisomicin: a review of eight years' experience". Rev Infect Dis. 2 (2): 182–195. doi:10.1093/clinids/2.2.182. PMID 6994206.

[pmid=649532-3] I Phillips, BA King, KP Shannon. (Mar 1978). "The mechanisms of resistance to aminoglycosides in the genus Pseudomonas". J Antimicrob Chemother. 4 (2): 121–129. doi:10.1093/jac/4.2.121. PMID 649532.

[pmid431401-4] ME Levison, D Kaye. (Mar 1979). "A randomized comparative trial of three aminoglycosides--comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies". Medicine (Baltimore). 58 (2): 159–170. doi:10.1097/00005792-197903000-00004. PMID 431401.

[5] DG Maki, WA Craig, WA Agger. (Jun 1979). "A comparative clinical trial of sisomicin and gentamicin in major gram-negative infections". Infection 7(Suppl. 3). 5 (6): 298–300. doi:10.1007/bf01646260.

[1]

[2]

[3]

[4]

[5]

Sisomicin

Overview

References

Navigation menu